Search
forLearn
5 / 801 resultslearn APISCALP™
learn pyrrolidone carboxylic acid
learn ppg-26-buteth-26
learn multipeptides
Research
5 / 1000+ resultsresearch Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth
Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.
research Effect of immunosuppressive ppiase inhibitors, cyclosporin A, FK506, ascomycin and rapamycin on hair growth initiation
Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.
research Studies of the modulation of MHC antigen and cell adhesion molecule expression on human dermal papilla cells
Different substances affect hair and skin cell growth in various ways, with some promoting and others inhibiting cell proliferation.
research The effects of extra cellular matrix and growth factors on dermal papilla cell proliferation
Different substances affect hair and skin cell growth in various ways.
research Italian Guidelines in diagnosis and treatment of alopecia areata
The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.
Community Join
5 / 1000+ results
community PP405 Identity Research
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
community Il PP405 è molto promettente ma non è l'unico in grado di liberarci dalla iattura
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.